Physician profile
Marla Driver
NPI 1396788808
$3,954.63
in general payments reported to CMS, 2019-2025
24 companies · $746 in 2025
The $746 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $769 · 2022: $1,000 · 2023: $771 · 2024: $667 · 2025: $746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,185.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $776.97 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $720.94 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $461.62 | 2021-2025 | |
| Abbvie INC. | $431.34 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $319.86 | 2021-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $265.84 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $147.24 | 2021-2025 | Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $109.94 | 2022-2024 | |
| Glaxosmithkline, LLC. | $98.97 | 2021-2024 | Trelegy Ellipta |
| Kowa Pharmaceuticals America, INC. | $87.23 | 2021-2023 | Livalo, Seglentis |
| Organon LLC | $71.47 | 2021-2023 | Nexplanon |
| Takeda Pharmaceuticals U.S.A., INC. | $69.34 | 2021-2022 | |
| Amgen INC. | $67.50 | 2024-2025 | Repatha, Otezla, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $58.60 | 2024-2025 | Caplyta |
| Ironshore Pharmaceuticals INC. | $55.68 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $37.65 | 2022 | |
| Biogen, INC. | $31.65 | 2021 | |
| Supernus Pharmaceuticals, INC. | $26.48 | 2025 | Qelbree |
| Exact Sciences Corporation | $22.50 | 2025 | The Cologuard Plus Collection Kit |
| Biohaven Pharmaceuticals, INC. | $21.97 | 2021 | |
| Eisai INC. | $19.32 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.86 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.69 | 2024 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $16.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marla Driver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.